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Human natural killer (NK) cells develop in secondary
lymphoid tissues (SLTs) through distinct stages. We
identified two SLT lineage (Lin)CD34CD117+/
CD94+CD16 ‘‘stage 4’’ subsets according to ex-
pression of the C-type lectin-like surface-activating
receptor, NKp80: NKp80 (stage ‘‘4a’’) and NKp80+
(stage ‘‘4b’’). Whereas stage 4b cells expressed
more of the transcription factors T-BET and EOMES,
produced interferon-gamma, and were cytotoxic,
stage 4a cells expressed more of the transcription
factors RORgt and AHR and produced interleukin-
22, similar to SLT LinCD34CD117+CD94CD16
‘‘stage 3’’ cells, whose phenotype overlaps with
that of group 3 innate lymphoid cells (ILC3s). Co-cul-
ture with dendritic cells or transplantation into immu-
nodeficient mice produced mature NK cells from
stage 3 and stage 4a populations. These data identify
NKp80 as a marker of NK cell maturity in SLTs and
support a model of human NK cell development
through a stage 4a intermediate with ILC3-associ-
ated features.
INTRODUCTION
Natural killer (NK) cells are innate lymphoid cells (ILCs) that can
kill pathogen-infected and malignant cells as well as modulate
other components of the immune system by producing chemo-
kines and cytokines. Numerous recent studies highlight the exis-
tence of other ILC populations, and collectively, all ILCs are now
categorized into three groups according to their differential
expression of surface antigens, transcription factors, and cyto-
kines (Spits et al., 2013). NK cells represent a subtype of group
1 ILCs, and their distinguishing features include (1) expression
of the transcription factors, T-BET and EOMES; (2) expressionThis is an open access article under the CC BY-Nof major histocompatibility complex (MHC) class I molecule-
binding receptors, CD94/NKG2 (considered specific for NK cells
among ILCs; Spits et al., 2013) and killer immunoglobulin-like
receptors (KIR); (3) production of interferon-gamma (IFN-g);
and (4) the ability tomediate perforin-dependent natural cytotox-
icity (Caligiuri, 2008; Cortez et al., 2015). ILC1s represent the
other group 1 ILC subtype (Spits et al., 2013). Whereas ILC1s
similarly produce IFN-g and express T-BET, recent mouse and
human studies indicate that they comprise a lineage that is
distinct from NK cells in that the former are non-cytolytic
and lack expression of numerous NK-associated molecules,
including EOMES, CD94, CD56, CD16, perforin, granzymes,
and KIRs (Bernink et al., 2013, 2015; Fuchs et al., 2013; Klose
et al., 2014).
Studies in both mice and humans indicate that NK cells can
develop in multiple tissues, including bone marrow (BM), sec-
ondary lymphoid tissues (SLTs), the liver, the uterus, and the
thymus (Yu et al., 2013). A five-stage model of human NK cell
development within SLTswas proposed based on the differential
expression of CD34, CD117, CD94, and CD16 among lineage
(Lin)-negative cells (i.e., cells lacking T, B, dendritic cell [DC],
and myelomonocytic-associated antigens): stage 1, CD34+
CD117CD94CD16; stage 2, CD34+CD117+CD94CD16;
stage 3, CD34CD117+CD94CD16; stage 4, CD34CD117+/
CD94+CD16; and stage 5, CD34CD117+/CD94+/CD16+
(Freud et al., 2014). The original study characterizing these
stages of development (Freud et al., 2006) showed that, in bulk
cultures, CD34+ stage 1 and stage 2 populations are capable
of DC, T cell, and NK cell differentiation, whereas the CD34
stage 3 population can give rise to NK cells, but not to DCs
or T cells. In addition, stage 3 cells lack the two hallmark func-
tions of mature NK cells (i.e., IFN-g production and perforin-
dependent cytotoxicity) that are detected at stage 4 (CD94+).
Therefore, it was originally concluded that stage 3 cells are line-
age-restricted NK cell precursors and that functional maturity is
acquired at stage 4 (Freud and Caligiuri, 2006). This NK cell
development model is supported by analysis of in-vitro-derived
intermediates (Grzywacz et al., 2006).Cell Reports 16, 379–391, July 12, 2016 ª 2016 379
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Identification of Two SLT Stage 4
Subsets according to NKp80 Expression
Representative flow cytometry analysis of nega-
tively enriched SLT ILCs (n = 10). Dot plots in the
top row were gated on SLT LinCD56+ lympho-
cytes. Dot plots in the bottom row were gated on
subsets within the SLT LinCD56+ population ac-
cording to NKp80 and CD16 expression as indi-
cated. S3, stage 3; S4a, stage 4a; S4b, stage 4b;
S5, stage 5. See also Figure S1.Subsequent studies showed that cells within the SLT stage 3
population express aryl hydrocarbon receptor (AHR), retinoic-
acid-receptor-related orphan receptor gamma (RORgt), inter-
leukin 22 (IL-22), IL-1R1, and IL-7Ra (CD127) (Cella et al.,
2009; Cupedo et al., 2009; Hughes et al., 2009, 2010, 2014;
Tang et al., 2011). These features have recently also been
associated with group 3 ILCs (ILC3), which in mice comprise a
lineage separate from that of conventional Eomes+ NK cells
(Hazenberg and Spits, 2014; Satoh-Takayama et al., 2010; Spits
et al., 2013; Vonarbourg et al., 2010). To the best of our knowl-
edge, it is not yet clear how best to distinguish between these
two human SLT populations ex vivo (Freud et al., 2014). Herein,
we refer to the SLT LinCD34CD117+CD94CD16 population
as ‘‘stage 3’’.
In this study, we identified two subsets of SLT stage 4 cells
according to the expression of the C-type lectin-like surface-
activating receptor, NKp80 (Bartel et al., 2013): NKp80 (stage
‘‘4a’’) and NKp80+ (stage ‘‘4b’’). Whereas stage 4b cells ex-
pressed more of the transcription factors T-BET and EOMES,
produced IFN-g, and were cytotoxic, stage 4a cells on the
other hand expressed more RORgt and AHR and produced
IL-22. Following in vitro co-culture with DCs or in vivo trans-
plantation into immunodeficient mice, stage 4a cells (as well
as stage 3 cells) gave rise to mature NK cells. These data refine
the previous model of human NK cell development in SLTs and
identify NKp80 as a marker of functional maturity ex vivo. In
addition, these data suggest that human NK cells and ILC3s
share a close developmental relationship, as we provide
compelling evidence that, in humans, NK cells can develop
in vivo through a stage 4a intermediate with ILC3-associated
features.380 Cell Reports 16, 379–391, July 12, 2016RESULTS
Identification of Two SLT Stage 4
Subsets according to NKp80
Expression
As previously described (Freud and Cali-
giuri, 2006; Freud et al., 2006) and shown
here in Figure 1 (top row, left dot plot),
visualizing CD94 versus CD117 expres-
sion among total freshly enriched SLT
LinCD56+ cells revealed a continuum of
events between the CD117+CD94 stage
3 and CD117+/CD94+ stage 4 NK cell
populations, suggestive of dynamic NK
cell development in situ. We observedthat stage 3 cells as well as the intermediate CD94+ cells directly
emerging from stage 3 lacked expression of the activating re-
ceptor, NKp80 (Figure 1, top row, middle dot plot), which was
detectable on the surface of virtually all NK cells in healthy hu-
man peripheral blood (PB) (Figure S1). We also observed that
nearly all SLT LinCD56+CD16+ cells (i.e., stage 5 cells) co-ex-
pressed NKp80 (Figure 1, top row, right dot plot).
By gating on SLT LinCD56+ subsets according to the differ-
ential expression of NKp80 and CD16 and then viewing CD94
versus CD117 expression, we confirmed that the aforemen-
tioned CD94+ intermediate population emerging from stage 3
lacked both NKp80 and CD16 expression (Figure 1, bottom
row). These ex vivo flow cytometry data suggested a stepwise
acquisition of CD94, NKp80, and CD16 during human NK cell
development in SLTs. Moreover, they revealed two distinct
SLT LinCD94+CD16 stage 4 NK cell subsets based on the dif-
ferential expression of NKp80. In keeping with the previous
model designating stage 4 NK cells as CD94+ and stage 5 NK
cells as CD16+ (Freud et al., 2014), we now refer to LinCD94+
NKp80CD16 cells as stage ‘‘4a,’’ LinCD94+NKp80+CD16
cells as stage ‘‘4b,’’ and LinCD94+/NKp80+CD16+ cells as
stage 5 (Figure 1, bottom row). We note that, although CD56
was expressed by many stage 3 cells and by most stage 4a,
4b, and 5 cells in SLTs, CD56 was not uniformly expressed by
each of these populations (see Figure 4A below; Freud et al.,
2006). Therefore, we did not include CD56 as a defining marker
of these populations but rather used it as a relatively specific
marker to help visualize patterns of antigen loss and acquisition
during NK cell development in SLTs. Using this approach, we
also observed that, just like stage 3 cells (LinCD117+
CD94NKp80CD16), stage 4a cells were naturally enriched
Figure 2. Stage 3 and Stage 4a Cells Are
Naturally Enriched in Human SLTs
Representative flow cytometry analyses of
LinCD56+ ILCs negatively enriched from pediatric
tonsil (n = 10), adult axillary lymph node (n = 4),
adult PB (n = 5), UCB (n = 3), and adult BM (n = 3)
specimens. Dot plots in each row were gated on
LinCD56+ lymphocytes. Circles and squares refer
to indicated populations in the dot plots.in SLTs (tonsils and lymph nodes), whereas they were extremely
rare if not undetectable in healthy adult PB, umbilical cord blood
(UCB), and adult BM samples (Figure 2). In contrast, stage 5 cells
represented the major NK cell population in blood and BM.
SLT Stage 4a Cells Lack Mature NK Cell Functions
In order to characterize the SLT stage 4a and 4b subsets, we
tested these cells for numerous phenotypic and functional pa-
rameters ex vivo. Stage 3 and stage 5 cells were tested in parallel
for comparison. We first observed a striking correlation between
surface NKp80 and intracellular perforin expression among
total SLT Lin cells (Figure 3A), indicating that stage 4a cells,
like stage 3 cells, lacked perforin expression. In addition, weCobserved that stage 3 and stage 4a cells
lacked intracellular expression of gran-
zymes A, B, and K, whereas these mole-
cules were at least partially expressed
by stage 4b and stage 5 cells (Figure 3B).
T-BET and EOMES protein expression
were also very low or undetectable within
stage 3 and stage 4a cells yet clearly ex-
pressed by stage 4b and 5 cells (Fig-
ure 3B). These intracellular flow cytometry
data were supported by quantitative real-
time RT-PCR analyses of TBX21 (encod-
ing T-BET) and EOMES expression by
SLT stage 3–stage 5 cells (Figure 3C)
that were freshly purified from SLTs by
cell sorting (Figure S2). Consistent with
these ex vivo phenotypic and quantitative
real-time RT-PCR data, freshly purified
SLT stage 3 and stage 4a cells failed to
mediate perforin-dependent cytotoxicity
against the MHC class I molecule-nega-
tive target cell line, K562, whereas stage
4b and stage 5 cells lysed K562 targets
(Figure 3D). Moreover, stage 4b and
stage 5 cytotoxicity was augmented
when IL-2 was present during the 4-hr
cytotoxicity assay, whereas IL-2 did not
impact the cytotoxic functions of stage 3
and stage 4a cells (Figure 3D). Freshly iso-
lated stage 3 and stage 4a cells also pro-
duced negligible amounts of IFN-g as
measured by ELISA. In contrast, stage
4b and stage 5 cells produced IFN-g as
detected by ELISA (Figure 3E) and byintracellular flow cytometry (Figure S3), and stage 4b cells
showed significantly higher production of IFN-g in comparison
to stage 5 cells. Thus, stage 4a cells lacked mature NK cell func-
tions ex vivo, and NKp80 expression within the originally
described stage 4 population (Freud et al., 2006) closely corre-
lated with mature NK cell functionality in SLTs.
SLT Stage 4a Cells Have Both NK- and ILC3-Associated
Features
Additional ex vivo analyses of stage 4a cells from human SLTs
revealed that these cells expressed numerous NK-cell-associ-
ated surface antigens and functional receptors, including CD56
as well as lymphocyte-function-associated antigen (LFA)-1,ell Reports 16, 379–391, July 12, 2016 381
Figure 3. NKCell Functional Maturity Corre-
lates with NKp80 Expression in SLTs
(A) Representative flow cytometry analysis of Lin-
enriched ILCs from SLT, showing the close corre-
lation between surface NKp80 expression and
intracellular perforin (n = 4).
(B) Representative flow cytometry analyses of
freshly enriched SLT stage 3–stage 5 cells,
showing intracellular expression of the indicated
proteins (n = 4). Histogram data were generated
by gating on Lin ILC populations as defined in
Figure 2.
(C) Transcriptional expression analysis by quanti-
tative real-time RT-PCR of TBX21 and EOMES by
freshly purified SLT stage 3–stage 5 cells. Data are
represented as mean ± SEM (n = 6). Increasing
trends of gene expression from stage 3 (values set
to 1 in a.u.) to stage 5 were statistically significant
(p < 0.0001 for each trend) as estimated using
linear mixed models based on the ddCT method.
(D) Specific lysis of K562 target cells by freshly
purified SLT stage 3–stage 5 cells in media alone
or in the presence of IL-2. Data are represented
as mean ± SEM (n = 4; n.s., not significant;
*p < 0.0001; **p = 0.0003).
(E) Quantitative ELISA data showing IFN-g pro-
duction by freshly purified SLT stage 3–stage 5
cells stimulated with IL-12, IL-15, and IL-18.
Data are represented as mean ± SEM (n = 7;
***p = 0.0021).
See also Figures S2 and S3.2B4, CD122, NKG2D, and NKp46. For most of these surface an-
tigens, with the exception of NKG2D, stage 4a expression levels
were intermediate between those of stage 3 cells (partial and/or
low) and those of stage 4b and stage 5 cells (high; Figure 4A).
NKp30 was nearly uniformly expressed by SLT stage 3–stage
5 cells, whereas NKp44 was expressed by subsets of the four
populations. Nearly all stage 4a cells expressed NKG2A and
lacked NKG2C and KIRs. In contrast, NKG2C+ and KIR+ subsets
were detected within the stage 4b and stage 5 populations (Fig-
ure 4A). Some CD57 expression, which is associated with termi-
nal differentiation among human PB NK cells (Lopez-Verge`s
et al., 2010), was detected within stage 5, but not within stage
3–stage 4b populations (n = 4; data not shown).
We also evaluated SLT stage 3–stage 5 cells for the expres-
sion of other ILC-associated surface antigens. CD161 was ex-
pressed at high levels on stage 3 and stage 4a cells, whereas382 Cell Reports 16, 379–391, July 12, 2016stage 4b and stage 5 cells showed vari-
able CD161 expression ranging from
high to partially low or negative. CD101,
CD103, CD160, and CXCR3 expression
has been described on human ILC1 cells
(Bernink et al., 2013; Fuchs et al., 2013),
and we observed that CD101 and
CD103 molecules were detected among
minor fractions of stage 3–stage 5 cells
(Figure 4A; data not shown). In contrast,
CD160 was primarily restricted to minor
subsets of stage 4b and stage 5 cellsamong total Lin cells. CXCR3 expression was low or undetect-
able at stage 3, intermediate at stage 4a, and highest at stages
4b and 5 (Figure 4A).
Regarding ILC3-associated features, we observed that,
similar to stage 3 cells, stage 4a cells, which were CD94+, ex-
pressed intermediate to high levels of IL-1R1, CD127, AHR,
and RORgt (Figure 4A, bottom row). In contrast, stage 4b and
stage 5 cells showed low or undetectable expression of these
molecules by flow cytometry. We confirmed by quantitative
real-time RT-PCR that stage 4a cells expressed mRNA tran-
scripts forAHR and isoform 2 of theRORC locus (RORC2), which
encodes for RORgt protein (Figure 4B), and we also observed
that stage 4b and stage 5 cells expressed detectable, albeit
very low, mRNA from both genes (Figure 4B). As shown in Fig-
ure 4C, freshly purified SLT stage 4a cells produced IL-22
following overnight stimulation with IL-1b and IL-23, and the
Figure 4. SLT Stage 4a Cells Show Both NK- and ILC3-Associated Features
(A) Representative flow cytometry analyses of freshly enriched SLT stage 3–stage 5 cells showing relative surface and intracellular expression of the indicated
antigens (n = 4). Histogram data were generated by gating on Lin ILC populations as defined in Figure 2.
(B) Transcriptional expression analysis by quantitative real-time RT-PCR of AHR and RORC2 by freshly purified SLT stage 3–stage 5 cells. Data are represented
asmean ±SEM (n = 6). Decreasing trends of gene expression from stage 3 (values set to 1 in a.u.) to stage 5were statistically significant (p < 0.0001 for each trend)
as estimated using linear mixed models based on the ddCT method.
(C) Quantitative ELISA data showing IL-22 production by freshly purified SLT stage 3–stage 5 cells stimulated with IL-1b and IL-23. Data are represented as
mean ± SEM (n = 6). A linear mixed effect model was used to evaluate the trend of IL-22 production from stage 3 to stage 5 cells (p < 0.0001).
See also Figure S2 and Table S1.
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Figure 5. ILC3-Associated Features of
CD94/NKG2A+ Stage 4a Cells
(A) Representative flow cytometry analysis of IL-22
production by SLT-enriched ILCs stimulated for
6 hr in PMA, ionomycin, and IL-2 (n = 4).
(B) Representative flow cytometry analysis of
freshly enriched and unstimulated SLT ILCs (n = 4).
Dot plots in (A) and (B) were gated on Lin lym-
phocytes enriched from pediatric tonsils.amounts of IL-22 produced were significantly lower compared to
donor-matched stage 3 cells. In contrast, stage 4b and stage 5
cells produced negligible amounts of IL-22.We further evaluated
IL-22 production by intracellular flow cytometry following a 6-hr
stimulation of freshly enriched SLT ILCs with phorbol 12-myris-
tate 13-acetate (PMA), ionomycin, and IL-2. As shown in Fig-
ure 5A, IL-22 production was detected by LinCD94/NKG2A+
cells, but not by Lin cells expressing KIRs, NKp80, NKG2C,
CD57, or CD16 (Figure 5A; data not shown). Likewise, many
LinCD94/NKG2A+ cells co-expressed CD127 and IL-1R1,
whereas most LinKIR+ cells did not (Figure 5B). Collectively,
these immunophenotypic and functional data indicate that
SLT stage 4a cells are CD94/NKG2A+NKp80CD16KIR
NKG2CCD57 and have some ILC3-associated features
ex vivo.384 Cell Reports 16, 379–391, July 12, 2016DCs Promote the Differentiation
andMaturation of Stage3 andStage
4a Cells In Vitro
We and others previously demonstrated
that human stage 3 cells as well as mature
NK cells closely associate with CD11c+
DCs in situ in SLTs (Ferlazzo et al., 2004;
Hughes et al., 2010). DCs can also pro-
mote mature NK cell homeostasis in vivo
in mice (Guimond et al., 2010). We there-
fore hypothesized that human DCs could
promote NK cell differentiation in vitro
from human SLT NK cell precursors.
Consistent with this hypothesis, we
observed that co-culture of allogeneic
monocyte-derived DCs with either stage
3 or stage 4a cells promoted robust
acquisition or maintenance of CD94
expression, respectively, compared to
cultures in cytokines (flt3 ligand [FL],
c-kit ligand [KL], and IL-15) alone (Figures
6A and 6B). This was observed in bulk
cultures (Figures 6A and 6B) as well as
in clonal assays comparing individually
sorted stage 3 cells cultured with either
activated peripheral blood mononuclear
cells (PBMCs) or DCs (Figure 6C).
Although CD94+ cells were observed in
all of the analyzed stage-3-derived clones
regardless of culture condition (29 clones
total; cloning efficiency 10%–15%), the
percentages of CD94+ cells per stage-3-derived clone were significantly higher in the presence of DCs
compared to PBMCs (Figure 6C).
In contrast to freshly isolated SLT stage 3 and stage 4a cells
(Figure 3), the in-vitro-derived CD94+ cells isolated from stage-3-
and stage-4a-initiated bulk co-cultures with DCs expressed
T-BET, EOMES, perforin, and IFN-g (Figure 6D; data not shown).
In addition, stage-3- and stage-4a-derived CD94+ cells were
cytotoxic against K562 at levels comparable to CD94+ cells
generated from stage-4b-initiated and stage-5-initiated cultures
(Figure 6E), thus supporting their designation as functionally
mature NK cells. The CD94 cells derived in the co-cultures
with stage 3 cells and DCs either retained ILC3-associated fea-
tures or adopted an ILC1-like phenotype, expressing CD161,
T-BET, and IFN-g, but not EOMES (Figure S4; data not shown).
Human ILC3 conversion into ILC1s was recently reportedly
Figure 6. DCs Promote NK Cell Functional
Maturation of Stage 3 and Stage 4a Cells
In Vitro
(A) Representative flow cytometry analysis following
culture of purified SLT stage 3–stage 5 cells with IL-
15, FL, and KL (i.e., ‘‘cytokines’’) or with cytokines
plus DCs (n = 16). Dot plots were gated on
LinCD56+ viable lymphocytes.
(B) Percentages of CD94+ NK cells among total
LinCD56+ cells derived in vitro from purified SLT
stage 3–stage 5 cells cultured in cytokines with or
without DCs. Data are represented as mean ± SEM
(n = 16; *p < 0.0001).
(C) Percentages of CD94+ NK cells derived in vitro
from freshly purified and individually sorted SLT
stage 3 cells expanded in the presence of allogeneic
PBMCs and IL-2 or in the presence of IL-15, FL, KL,
and DCs. Pooled data from two separate experi-
ments are represented as mean ± SEM (n = 18 total
clones for PBMC condition; n = 11 total clones for
DC condition; *p < 0.0001).
(D) Representative intracellular flow cytometry
analysis of LinCD94+ NK cells derived in vitro from
bulk co-culture of SLT stage 3 cells with cytokines
and DCs (n = 4). IFN-g production was induced by
6 hr stimulation with PMA, ionomycin, and IL-2.
Black lines represent isotype control staining,
whereas shaded histograms represent staining with
antigen-specific antibodies.Data are similar to those
generated with LinCD94+ cells derived in vitro
from stage 4a cultures (n = 4; data not shown).
(E) Specific lysis of K562 target cells by purified
LinCD94+ cells derived in vitro from stage 3–stage
5 cells cultured with cytokines and DCs. Data are
represented as mean ± SEM (n = 5; n.s., not sig-
nificant).
(F) Representative flow cytometry analysis of SLT
stage 3 cells that were labeled with a membrane
tracer dye at day 0 and then cultured in vitro for
2 weeks with cytokines alone or cytokines plus
DCs (n = 2).
(G) Percentages of NKp80+ NK cells among total
LinCD56+ cells derived in vitro from purified SLT
stage 3–stage 5 cells cultured in cytokines with or
without DCs. Data are represented as mean ± SEM
(n = 10; **p = 0.0067; ***p = 0.045). For all culture ex-
periments, stage3–stage5 cellswere sorted to>99%
purity using the strategy depicted in Figure S2.
See also Figures S2, S4, and S5.induced by IL-12 (Bernink et al., 2013); however, this endoge-
nous cytokine was not required for the augmentation of CD94+
NK cell differentiation from stage 3 cells in the DC co-culture sys-
tem we used (Figure S5).
Cultures initiated with DCs alone without SLT-derived cells did
not contain any distinct LinCD161+CD94+/CD56+/ ILCs. In
addition, we observed similar inductions of CD94 expression
on stage 3 cells if they were co-cultured with DCs that had
been irradiated (data not shown), validating that these results
were not due to the outgrowth of PB NK cells contaminating
the DCs. We also performed membrane-tracer-labeling experi-
ments to confirm that the data were not the result of the selective
outgrowth of rare functionally mature CD94+ NK cells contami-
nating the sorted SLT stage 3 or stage 4a populations. For theseexperiments, tonsil-derived ILCs were first labeled with a mem-
brane tracer dye, and then tracer dye+ stage 3 cells were sorted
to >99%purity (data not shown). The purified tracer dye+ stage 3
cells were then cultured in FL, KL, and a very low dose of IL-15
(10 pg/ml; i.e., a 1,000-fold lower concentration than that used
throughout the rest of this study) in order tominimize proliferation
in vitro and hence promote retention of the tracer dye. As shown
in Figure 6F, after 2 weeks in cultures containing only cytokines,
essentially all cells retained themembrane tracer dye and did not
induce CD94 expression. In contrast, in the cultures containing
cytokines plus DCs, approximately half of the cultured stage 3
cells induced CD94 (Figure 6F). Despite the fact that at least
half of all the cells proliferated, as indicated by the loss of the
tracer dye in the presence of the DCs, a substantial proportionCell Reports 16, 379–391, July 12, 2016 385
of the CD94+ cells were tracer dye+ and thus had not significantly
proliferated (Figure 6F). These data confirm that NK cell differen-
tiation, represented by de novo CD94 induction, had occurred
from stage 3 cells and that the results were not due to themarked
proliferation of rare contaminating CD94+ NK cells.
Despite the acquisition of NK-cell-maturity-associated pheno-
typic and functional features following co-culture of DCs with
either stage 3 or stage 4a cells, NKp80 surface expression was
not induced (Figures 6A and 6G). Moreover, NKp80 expression
was significantly downregulated on stage 4b and stage 5 cells
following in vitro co-culture with DCs (Figure 6G), similar to
what occurs when PB NK cells are stimulated ex vivo (Klimosch
et al., 2013). Therefore, whereas NKp80 expression correlated
with NK cell functional maturity among ex-vivo-tested SLT
ILCs, NKp80 expression did not correlate with NK cell differenti-
ation following culture of stage 3 or stage 4a cells with DCs under
the in vitro conditions tested here.
SLT Stage 3 and Stage 4a Cells Undergo Terminal NK
Cell Development In Vivo
To test the NK cell developmental potential of SLT-derived stage
3 and stage 4a cells in a more-complex in vivo environment,
these cells were sorted to >99% purity, and then each popula-
tion was transplanted into busulfan-pretreated nonobese dia-
betic (NOD)-scid IL2Rgammanull (NSG) immunodeficient mice
that were then injected twice weekly with human IL-15. Analysis
of surface CD94, NKp80, and CD16 expression after 5 weeks
among human CD45+ cells revealed that transplanted stage 3
and stage 4a cells each showed evidence of downstream NK
cell maturation in the spleens (Figures 7A and S6) as well as in
the blood and BM (data not shown) of recipient NSG mice. No
human CD45+ lymphocytes were detected in control mice that
had not been transplanted with human cells (data not shown).
Moreover, the human CD45+ cells retrieved from transplanted
mice were LinCD56+, consistent with NK cells (data not shown).
In contrast to the observed NK cell differentiation in vitro (Fig-
ure 6), NKp80 was induced on the in vivo differentiated cells
derived from transplanted stage 3 or stage 4a cells. In addition,
variable proportions of LinCD94+NKp80+CD16+ (stage 5) cells
were derived in vivo, and some also expressed CD57 and/or
KIRs (Figures 7A and S6). Similar findings were observed when
purified SLT stage 4b and stage 5 cells (sorted as CD57KIR;
not shown) were transplanted into NSG mice (Figure S6). Thus,
under these in vivo conditions, SLT stage 3 cells and stage 4a
cells generated LinCD56+CD94+NKp80+CD16+CD57+/KIR+/
cells bearing the immunophenotype associated with terminally
differentiated human NK cells (Bjo¨rkstro¨m et al., 2010; Luetke-
Eversloh et al., 2013). Collectively, these data support a
model of human NK cell development in SLTs that incorporates
NKp80 expression into the existing framework of CD34, CD117,
CD94, and CD16 expression (Freud and Caligiuri, 2006; Freud
et al., 2014; Luetke-Eversloh et al., 2013; Yu et al., 2013;
Figure 7B).
DISCUSSION
In this study, we identified a LinCD117+/CD94+NKp80CD16
stage ‘‘4a’’ population that was naturally restricted to human386 Cell Reports 16, 379–391, July 12, 2016SLTs and that appeared to emerge directly from the
LinCD117+CD94NKp80CD16 stage 3 population. Whereas
stage 4a cells expressed many NK cell markers, including CD94/
NKG2A and NKG2D, they lacked hallmark features of mature NK
cells and rather showed an ILC3-like profile, similar to stage 3
cells, including expression of RORgt, AHR, IL-1R1, CD127,
and IL-22. In contrast, LinCD117+/CD94+NKp80+CD16
stage ‘‘4b’’ cells showed negligible ILC3-associated features
ex vivo and instead expressed T-BET, EOMES, and IFN-g, and
they could also mediate perforin-dependent cytotoxicity. We
also demonstrated that SLT stage 3 cells and stage 4a cells ac-
quired phenotypic and functional properties of mature NK cells
following in vitro co-culture with DCs as well as following in vivo
transplantation into NSGmice treated with IL-15. Thus, the stage
4a population appears to represent a naturally occurring pheno-
typic and functional developmental intermediate between the
stage 3 cell and the stage 4b NK cell in human SLTs.
Several points can be taken from this study. First, the demon-
stration that NKp80 expression closely correlates with NK cell
functional maturity in SLTs suggests that NKp80 may fulfill an
important regulatory role during the maturation process in
SLTs, potentially related to the acquisition of cytotoxic and/or
cytokine-producing functions. The fact that NKp80 stage 4a
cells expressed CD94/NKG2A yet were not mature in terms of
NK-related functions is also intriguing in light of compelling
mouse and human data indicating that MHC class I molecule-
binding inhibitory receptors influence NK cell maturation, a
process commonly referred to as ‘‘licensing’’ or ‘‘education’’
(Anfossi et al., 2006; Kim et al., 2005). Perhaps the transition
from stage 4a to stage 4b represents the initial education event
during human NK cell development in SLTs. Further studies
are warranted to investigate the roles of these surface receptors
during human NK cell development.
The identification of the stage 4a population that is naturally
enriched in SLTs provides additional evidence that human NK
cell development occurs in these tissues. The notion of extrame-
dullary humanNK cell development is supported by the prior dis-
covery of NK cell progenitors in SLTs (Freud et al., 2005) as well
as by the detection of unique tissue-resident NK cell populations
in other anatomical locations, such as the liver and uterus
(Moffett and Colucci, 2014; Sojka et al., 2014; Yu et al., 2013).
Future studies are warranted to determine whether similar
LinCD94+NKp80CD16 stage 4a cells are present in these
other extramedullary tissues, whether such cells show ILC3-
associated features, and/or whether NK cells derive in situ in
these tissues potentially through a stage 4a intermediate. The
fact that stage 4a cells were not enriched within the total
LinCD56+ population in adult BM suggests that human NK
cell development, if present in BM, proceeds through a different
pathway and/or that the pathway we describe is not prominent
there.
Our study also provides evidence supporting a role for DCs in
augmenting human NK cell maturation. Previous studies indi-
cated that mature NK cells interact with DCs in SLTs and that
reciprocal interactions between these two cell types are impor-
tant in both homeostatic and inflammatory settings (Cooper
et al., 2004; Ferlazzo et al., 2004; Guimond et al., 2010; Moretta,
2005). We have also previously reported that stage 3 cells are in
Figure 7. Stage 3 Cells Develop into NKp80+CD16+/ NK Cells In Vivo, Supporting a Model of Human NK Cell Development
(A) Representative flow cytometry analysis of SLT stage 3 cells freshly sorted to >99% purity using the strategy depicted in Figure S2 (top row) and after 5 weeks
in vivo following transplantation into an NSGmouse treated twice weekly with human IL-15 (n = 4). Dot plots in the top rowwere gated on viable lymphocytes. Dot
plots in the bottom rowwere gated on viable humanCD45+ lymphocytes isolated from the spleen of the engrafted NSGmouse. Quadrants were set with the aid of
isotype control staining. As shown in the bottom row, transplanted stage 3 cells gave rise to stage 4a, 4b, and 5 cells (black arrows). Cells expressing the NK cell
terminal maturation-associated markers, CD57 (red circle), and KIR (blue oval) were also detected.
(B) Proposed model of NK cell development in SLTs according to the expression of CD34, CD117, CD94, NKp80, and CD16.
See also Figure S6.close proximity to CD11c+ DCs in human SLTs (Hughes et al.,
2010). In the current study, we observed a significant induction
of CD94 that was accompanied by T-BET, EOMES, perforin,
and IFN-g expression when purified stage 3 cells were cultured
in the presence of FL, KL, IL-15, and DCs, but not when they
were cultured with cytokines alone. This DC-mediated effect
was not reliant on endogenous or exogenous IL-12. We also
observed the conversion of stage 3 cells into LinCD161+CD94
T-BET+EOMESIFN-g+ ILC1s in the DC co-cultures, similar tothe recently described conversion of human ILC3s into ILC1s
(Bernink et al., 2015). We therefore hypothesize that DCs can
support the differentiation and maturation of ILC1s as well as
NK cells in situ in SLTs, and future studies are warranted to
test this hypothesis and to elucidate the potential mechanism(s)
involved.
Lastly, these data provide evidence that, in contrast to mouse
NK cells, at least some human NK cells likely share a close
developmental relationship with ILC3s. Previous murine Rorc2Cell Reports 16, 379–391, July 12, 2016 387
fate-mapping studies indicate murine ILC3s (Rorc2 fate-map+)
comprise a lineage that is separate from that of conventional
NK cells (Rorc2 fate-map; Satoh-Takayama et al., 2010; Vonar-
bourg et al., 2010). These fate-mapping data coupled with the
recent identification in mice of common helper ILC progenitor
cells capable of giving rise to ILC1s, ILC2s, and ILC3s, but not
to NK cells (Constantinides et al., 2014; Klose et al., 2014), pro-
vided a clear rationale for empirically excluding any human
RORgt+ cell as representing a physiologic NK cell precursor.
Nonetheless, we show here that, at the population level,
stage 3–stage 5 cells in SLTs each expressed at least low levels
of detectable RORC2 transcript if not RORgt protein, and others
have shown that SLT LinCD34+CD45RA+CD117+ stage 2 cells
express RORgt (Cupedo et al., 2009; Montaldo et al., 2014). We
also recently demonstrated that human PB CD56bright NK cells,
which express CD94, CD117, CD127, and NKp80 (Cooper
et al., 2001; Matos et al., 1993; Romagnani et al., 2007; Vitale
et al., 2001; Vosshenrich et al., 2006), constitutively express
RORC2 and can derive from an SLT RORgt+ common ILC pro-
genitor population (Scoville et al., 2016). These data indicate
that, in humans, at least some PB NK cells would be fate-map+
for RORC2. Thus, there appears to be a distinct difference in
the lineage fidelities of RORC2 and Rorc2 expression in humans
and in mice, respectively, and at least some human NK cells can
develop through a RORgt+ pathway. However, this is not to say
that all human NK cells develop in this manner, and other path-
ways of human NK cell development may exist in vivo. Of note,
a recent study demonstrated that human patients with RORgt
deficiency had reduced PB ILC3s but normal numbers of PB
NK cells (Okada et al., 2015). The NK cells in those patients
were not evaluated functionally; however, those data indicate
that at least some human NK cells do not require RORgt for their
development in vivo.
In light of the aforementioned mouse and human Rorc2 and
RORC2 expression data, respectively, coupled with the demon-
stration here that SLT stage 4a cells express CD94/NKG2A, have
an ILC3-like profile, and in many ways have features intermedi-
ate between those of stage 3 cells and stage 4b cells, the distinc-
tion between stage 3NK cell precursors (presumed RORgt) and
ILC3s (RORgt+) in humans is unclear. We performed quantitative
real-time RT-PCR on 30 individually sorted stage 3 cells from
each of three separate donor tonsil samples, and we detected
RORC2 expression in 78% of cells (Table S1). Whereas the pos-
itive control gene,CD45, was also detected in only 78%of sorted
cells, these single-cell quantitative real-time RT-PCR data sug-
gest that not all stage 3 cells necessarily express RORC2 and
that there may be heterogeneity within this population. Indeed,
other groups have investigated the latter possibility. For
example, Ahn et al. (2013) showed that CD7 and LFA-1 could
distinguish stage 3 NK cell precursors from ILC3s within the
LinCD117+CD94 population derived in vitro following culture
of human UCB CD34+ cells. However, here, we demonstrated
that all freshly purified SLT stage 3 cells (as well as all stage
4a, 4b, and 5 cells) expressed LFA-1. In addition, we have
observed that some cells within stages 3–5 in SLTs are CD7
(A.G.F. and K.A.K., unpublished data). Therefore, LFA-1 and/or
CD7 are not sufficient ex vivo to distinguish SLT NK cell precur-
sors from ILC3s.388 Cell Reports 16, 379–391, July 12, 2016In a separate study working with freshly purified human tonsil
LinCD161+CD117+ cells, Crellin et al. (2010) showed that a mi-
nor CD127 fraction preferentially generated NK cells following
in vitro culture with cytokines and stimulated PBMCs, whereas
the predominant CD127+ fraction primarily retained ILC3 fea-
tures under these culture conditions. The authors concluded
that CD127 expression distinguishes stage 3 NK cell precursors
from ILC3s. However, in that study, CD94 was not used to
exclude mature NK cells during the purification procedure, and
as shown here and also as reported by others, mature SLT NK
cells and PBCD56bright NK cells can express CD127 (Romagnani
et al., 2007; Vosshenrich et al., 2006). In addition, we have previ-
ously demonstrated (Freud et al., 2006; Hughes et al., 2014) and
also show here with our DC co-culture and in vivo transplantation
experiments that NK cell differentiation is significantly influenced
by the microenvironment. Thus, it is possible that the results and
conclusions presented in the Crellin et al. study were impacted
by the culture conditions employed and/or by the preferential
expansion of CD94+ NK cells that may have been present in
the starting LinCD161+CD117+CD127 populations. As such
and in light of the data presented here, to the best of our knowl-
edge, there is still no reliable method to distinguish stage 3 NK
cell precursors from ILC3s ex vivo, and it remains possible that
these populations comprise the same cell type. Further investi-
gation is needed.
In summary, we have identified two distinct subsets of SLT
stage 4 cells: an NKp80 stage 4a population with both NK-
and ILC3-associated features as well as an NKp80+ stage 4b
population with phenotypic and functional attributesmost similar
to PB CD56bright NK cells. Our combined ex vivo, in vitro, and
in vivo data indicate that NKp80 marks a critical step in human
NK cell development and that a physiologic pathway of human
NK cell development likely exists in SLTs through a stage 4a in-
termediate with ILC3-associated features.
EXPERIMENTAL PROCEDURES
Tissue Collection
All tissues were collected under protocols approved by the OSU Institutional
Review Board and performed in accordance with approved guidelines. Fresh
human pediatric tonsils were obtained through the NCI-approved Cooperative
Human Tissue Network (CHTN) from Nationwide Children’s Hospital. Adult PB
leukopaks were obtained from the American Red Cross. Human UCB and BM
specimens were obtained through the Translational Cell Processing Core at
Cincinnati Children’s Hospital Medical Center (CCHMC). Clinically benign
adult axillary lymph nodes were procured from breast cancer patients under-
going elective prophylactic or therapeutic mastectomies.
Cell Isolation
ILCs were enriched from SLTs as described (Scoville et al., 2015). Briefly, sin-
gle-cell suspensionswere generated fromSLTs by automated dissociation us-
ing the GentleMACs benchtop instrument (Miltenyi Biotec) on the ‘‘Spleen 1’’
setting, according to manufacturer’s instructions. The cells were then resus-
pended in fetal bovine serum (FBS) (Sigma-Aldrich), leukocyte-depleted allo-
geneic ABRh+ red blood cells (RBCs) (The American RedCross), and a custom
Human NK cell enrichment RosetteSep reagent (STEMCELL Technologies)
containing a cocktail of bivalent antibodies against glycophorin A and CD3,
CD4, CD19, CD20, CD36, CD66b, and CD123. ILCs were enriched from adult
human leukopak (i.e., PB), BM, and UCB samples using the standard Human
NK cell enrichment RosetteSep reagent. PB monocytes were enriched from
adult leukopaks using the Human Monocyte enrichment RosetteSep reagent
(STEMCELL Technologies). Samples mixed with RosetteSep reagents were
incubated for 30 min at room temperature on a nutator, diluted in PBS (GE
Healthcare), layered over Ficoll-Paque PLUS (GE Healthcare), and then centri-
fuged at 754 3 g for 30 min at room temperature with the brake off. The
monolayers were harvested, and remaining RBCs were removed using an
ammonium chloride RBC lysis buffer (STEMCELL Technologies). Monocytes
were further enriched using the human CD14+ cell isolation kit (Miltenyi Biotec)
followed by fluorescence-activated cell sorting (FACS) purification of CD14+
cells to >99% purity using a FACSAriaII sorter (BD Biosciences). For all exper-
iments, NK cell developmental stages were sorted to >99% pure from tonsil
ILC-enriched mononuclear fractions using a FACSAriaII sorter. Stage 3 cells
were sorted as LinCD117+CD94NKp80CD16, stage 4a cells were sorted
as LinCD94+NKp80CD16, stage 4b cells were sorted as LinCD94+
NKp80+CD16, and stage 5 cells were sorted as LinCD94+NKp80+CD16+
(Figure S2). Throughout the manuscript, ‘‘Lin’’ refers to the following antigens:
CD3, CD14, CD19, CD20, and CD34.
Flow Cytometry
Flow cytometry immunophenotyping was performed using an LSRII cytometer
(BD Biosciences) as previously described (Scoville et al., 2015). Isotype-
matched or unstimulated controls were used when appropriate to determine
the level of nonspecific staining. Sytox V500 (Life Technologies) and AquaBlue
(Life Technologies) viability dyes were utilized to exclude non-viable cells in the
analyses. The Supplemental Experimental Procedures contains a list of the an-
tibodies used. Data were analyzed using either FACSDiva (BD Biosciences) or
FlowJo (TreeStar) software.
Real-Time RT-PCR
mRNAwas isolated and purified using the Total RNA Purification Kit according
to themanufacturer’s instructions (Norgen Biotek), and cDNAwas synthesized
using the Superscript VILO Master Mix (Life Technologies). A Viia7 Real-Time
PCR System (Life Technologies) was used to run standard quantitative real-
time PCR reactions using custom primers (Sigma-Aldrich) specifically target-
ing the following genes: TBX21, EOMES,RORC2, andAHR. The Supplemental
Experimental Procedures contains the primer sequences for each gene tested.
Gene expression was normalized to the GAPDH mRNA internal control
(DCt = Ct gene of interest  Ct GAPDH). Relative mRNA expression for each
target was calculated as 2-(DCt).
Cytokine Production and Cytotoxicity Assays
Purified SLT cells were resuspended at 5E4 cells/ml in RPMI-1640 culture me-
dia containing 10%FBS (Sigma-Aldrich), 1% antibiotic/antimycotic (Life Tech-
nologies), and 1% HEPES buffer (Life Technologies). Two hundred microliters
was added to each well of a 96-well round-bottom plate (Corning), and the
cells were stimulated for 16 hr at 37C in media only; in 10 ng/ml recombinant
human IL-1b (Miltenyi Biotec) plus 10 ng/ml recombinant human IL-23 (Miltenyi
Biotec); or in 10 ng/ml recombinant human IL-12 (Amgen), 10 ng/ml recombi-
nant human IL-15 (Miltenyi Biotec), and 10 ng/ml recombinant human IL-18
(Amgen). Following the stimulations, supernatants were frozen at 80C until
they were thawed and analyzed by ELISA as previously described (Freud et al.,
2006). For intracellular cytokine detection by flow cytometry, tonsil ILC-
enriched mononuclear cells were incubated with either cytokines or with a
combination of PMA/ionomycin (eBiosciences) and 1 nM recombinant human
IL-2 (PeproTech) plus brefeldin A (BD Biosciences) at 37C. After 6 hr, the cells
were harvested, stainedwith antibodies against cell surface antigens, and then
permeabilized using Cytofix/Cytoperm (BD Biosciences). The cells were then
stained with antibodies against IL-22 and/or IFN-g and finally fixed with 1%
formalin prior to performing flow cytometry. For cytotoxicity assays, purified
cells were tested against K562 targets at a 40:1 effector:target cell ratio in
4-hr 51Cr release assays in RPMI-1640 medium with or without 1 nM IL-2 as
previously described (Freud et al., 2005).
Cell Culture
Purified tonsil-derived populations were cultured for 2 weeks at a concentra-
tion of 5E3 cells/ml in 200 ml culture medium per well in 96-well flat-bottom
plates (Corning) in the presence or absence of 1.5E5 allogeneic monocyte-
derived DCs (see below). For some experiments, the DCs were irradiated(3E3 rad) prior to co-culture. The culture medium for these experiments con-
sisted ofMEM-a (Life Technologies) plus 10%FBS, 1% antibiotic/antimycotic,
1% HEPES buffer, recombinant human KL (100 ng/ml; Amgen), recombinant
human FL (100 ng/ml; Miltenyi Biotec), and recombinant human IL-15
(10 ng/ml; Miltenyi Biotec). For cloning experiments with DCs, single stage 3
cells were individually sorted from bulk-sorted stage 3 preparations (i.e., two
rounds of sorting) into wells of 96-well round-bottom plates containing
200 ml MEM-a media with 5E4 DCs. For cloning experiments with PBMCs, in-
dividual stage 3 cells were directly sorted into wells of 96-well round-bottom
plates containing 5E4 irradiated (3E3 rad) PBMCs pooled from three allogeneic
PB samples in RPMI-1640 media plus 10% FBS, 1% antibiotic/antimycotic,
1%HEPES buffer, 1 nM recombinant human IL-2, and 5E4 Human T-Activator
CD3/CD28 Dynabeads (Life Technologies). Fresh irradiated PBMCs and acti-
vator beads were replenished at day 10. Clones were grown for 4 weeks, and
wells with visible growth after this time period were analyzed by flow cytome-
try. For all cultures, half the media was replaced with 23 cytokines every
3–5 days. In order to derive DCs in vitro, purified monocytes were cultured
for 6 days in MEM-a medium plus 10% FBS, 1% antibiotic/antimycotic,
1% HEPES buffer, 10 ng/ml recombinant human IL-4 (Miltenyi Biotec), and
10 ng/ml recombinant human GM-CSF (Miltenyi Biotec). Half the medium
was then replaced with 20 ng/ml IL-4 and GM-CSF plus 20 ng/ml recombinant
human tumor necrosis factor alpha (TNF-a) (Miltenyi Biotec) and 20 ng/ml pu-
rified lipopolysaccharide (Sigma-Aldrich) for 2 more days of culture to mature
the DCs. For the cell membrane tracer experiments, enriched tonsil-derived
ILCs were stained with antibodies for cell sorting as well as with 5 mM of a
membrane tracer dye (Cell Proliferation Dye eFluor 670; eBioscience), and
then tracer dye+ stage 3 cells were sorted to >99% purity. The sorted cells
were then co-cultured in bulk for 2 weeks with or without DCs as described
above, albeit with IL-15 used at a concentration of 10 pg/ml.
Transplantation Experiments in NSG Mice
The in vivo experiments with NSG mice (The Jackson Laboratory) were per-
formed in accordance with an approved OSU Institutional Animal Care and
Use Committee protocol. Six- to ten-week-old female NSG mice were treated
with 25mg/kg busulfan 1 day prior to injection of purified human tonsil-derived
cells in order to promote engraftment. The next day 5E3–1E5 purified NK cell
developmental intermediates were injected intravenously into the tail veins of
the NSG mice immediately after sorting. At day 0 and twice weekly thereafter
for 5 weeks, the mice were given intraperitoneal injections of recombinant hu-
man IL-15 (0.5 mg). Five weeks following transplantation, the mice were sacri-
ficed, and their spleens, blood, and BM cells were harvested and then
analyzed by flow cytometry. During the latter, murine leukocytes were
excluded using an anti-mouse CD45.1 antibody (BD Biosciences). Human leu-
kocytes were identified with an anti-human CD45 antibody (Miltenyi Biotec).
Statistical Analysis
Linear mixed effects models were used for analysis to take account of the cor-
relation among observations from the same donor. The differences between
conditions were estimated from those models. Holm’s procedure was used
to adjust for multiple comparisons. After adjustment for multiple comparisons,
p values < 0.05 were considered significant. Summary statistics, such asmean
and SD, were provided for all variables. SAS 9.4 was used for analysis (SAS
Institute).
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